The Fujian Provincial Economic and Trade Commission recently issued the "Twelfth Five-Year Development Plan for Fujian's Pharmaceutical Industry." It clearly puts forward efforts to guide strategic mergers and acquisitions and reorganization of enterprises, and to expand the industrial scale. By 2015, the total industrial output value will reach 55 billion yuan, with an average annual growth rate of 25%. . Among the local listed companies, Jindawei's nutritional fortifier project was selected as the “12th Five-Year Plan†key project, and Pien Tze Huang was selected as the “Twelfth Five-Year Plan†to focus on the development of key enterprises.
According to the plan, Fujian will encourage the implementation of restructuring and integration, support upstream and downstream integration among pharmaceutical companies, improve the industrial chain, and improve the efficiency of resource allocation. Nurtured and formed three industrial enterprises with sales revenues of RMB1.5 billion or more and three companies with RMB10.5 billion to RMB1.5 billion, and completed the financing of the listing of three pharmaceutical companies.
In addition, Fujian will improve the construction of biomedical industry parks in the economic zone on the west side of the Straits in Fuzhou, Xiamen, Mingxi, and Qirong, among which Xiamen Haicang Biopharmaceutical Concentration Zone will focus on the development of genetic engineering drugs, modern Chinese medicine, marine drugs, and natural resources. Drugs, new drug preparations, etc.
The Jindawei Nutrition Enhancer Project, which was included in the “Twelfth Five-Year Plan†key project of Fujian's pharmaceutical industry, was built in Xinyang Industrial Zone, Haitang, Xiamen. The total investment of the project is 125 million yuan, of which, the investment in fixed assets is 119 million yuan. It mainly constructs production workshops, auxiliary production buildings, experimental and laboratory centers, and office space. The project will build a production capacity of 5,000 tons of nutrition enhancer and additive products with an annual output of approximately 300 million yuan.
It is understood that this project will be commissioned and put into production in 2012, and production capacity will be gradually released from 2012. In the first half of the year, Jindawei achieved revenue of 330 million yuan, a year-on-year increase of 15.24%, of which Coenzyme Q10 achieved revenue of 108 million yuan, a year-on-year increase of 26.47%. In addition, the company's Coenzyme Q10 expansion project is expected to be put into operation in the second half of 2012. After the production, Coenzyme Q10's production capacity in the second half of the year is expected to increase by another 30%.
In supporting policies, Fujian Province will increase investment in strategic emerging industries, support the development of key areas in the biomedical industry, improve the establishment of a special fund system for supporting production of traditional Chinese medicinal materials, and support the protection and development of Chinese herbal medicine resources. A group of key projects are recommended. Inclusion in various special investment plans of the central government. In addition, qualified pharmaceutical companies will also be encouraged to list funds and issue bonds on domestic and foreign capital markets, and guide the use of raised funds for technological innovation and new product development. We will implement policies such as deduction of R&D expenses and preferential income tax for hi-tech enterprises, and improve and implement tax support policies that encourage innovation.
According to the plan, Fujian will encourage the implementation of restructuring and integration, support upstream and downstream integration among pharmaceutical companies, improve the industrial chain, and improve the efficiency of resource allocation. Nurtured and formed three industrial enterprises with sales revenues of RMB1.5 billion or more and three companies with RMB10.5 billion to RMB1.5 billion, and completed the financing of the listing of three pharmaceutical companies.
In addition, Fujian will improve the construction of biomedical industry parks in the economic zone on the west side of the Straits in Fuzhou, Xiamen, Mingxi, and Qirong, among which Xiamen Haicang Biopharmaceutical Concentration Zone will focus on the development of genetic engineering drugs, modern Chinese medicine, marine drugs, and natural resources. Drugs, new drug preparations, etc.
The Jindawei Nutrition Enhancer Project, which was included in the “Twelfth Five-Year Plan†key project of Fujian's pharmaceutical industry, was built in Xinyang Industrial Zone, Haitang, Xiamen. The total investment of the project is 125 million yuan, of which, the investment in fixed assets is 119 million yuan. It mainly constructs production workshops, auxiliary production buildings, experimental and laboratory centers, and office space. The project will build a production capacity of 5,000 tons of nutrition enhancer and additive products with an annual output of approximately 300 million yuan.
It is understood that this project will be commissioned and put into production in 2012, and production capacity will be gradually released from 2012. In the first half of the year, Jindawei achieved revenue of 330 million yuan, a year-on-year increase of 15.24%, of which Coenzyme Q10 achieved revenue of 108 million yuan, a year-on-year increase of 26.47%. In addition, the company's Coenzyme Q10 expansion project is expected to be put into operation in the second half of 2012. After the production, Coenzyme Q10's production capacity in the second half of the year is expected to increase by another 30%.
In supporting policies, Fujian Province will increase investment in strategic emerging industries, support the development of key areas in the biomedical industry, improve the establishment of a special fund system for supporting production of traditional Chinese medicinal materials, and support the protection and development of Chinese herbal medicine resources. A group of key projects are recommended. Inclusion in various special investment plans of the central government. In addition, qualified pharmaceutical companies will also be encouraged to list funds and issue bonds on domestic and foreign capital markets, and guide the use of raised funds for technological innovation and new product development. We will implement policies such as deduction of R&D expenses and preferential income tax for hi-tech enterprises, and improve and implement tax support policies that encourage innovation.
Soy Sauce,Mushroom Soy Sauce,Healthy Soy Sauce,Light Soy Sauce And Dark Soy Sauce
Desly Foods Co.,Ltd. , https://www.deslygroup.com